Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol epilepsy:

Search results

Items: 1 to 20 of 186

1.

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, Klamt F.

CNS Drugs. 2018 Aug 14. doi: 10.1007/s40263-018-0550-4. [Epub ahead of print]

PMID:
30109642
2.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Aug 9. pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020. [Epub ahead of print]

3.

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.

Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA.

Med J Aust. 2018 Aug 13. [Epub ahead of print]

PMID:
30092753
4.

Safety of cannabidiol prescribed for children with refractory epilepsy.

Freeman JL.

Med J Aust. 2018 Aug 13. [Epub ahead of print] No abstract available.

PMID:
30092751
5.

Cannabis for pediatric epilepsy: protocol for a living systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter B, Skidmore B, Alexander C, Repetski AE, McCoy B, Wells GA.

Syst Rev. 2018 Jul 18;7(1):95. doi: 10.1186/s13643-018-0761-2.

6.

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.

Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D.

Epilepsy Behav. 2018 Jul 11. pii: S1525-5050(18)30191-4. doi: 10.1016/j.yebeh.2018.05.013. [Epub ahead of print]

7.

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.

Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R; CBD EAP study group.

Epilepsia. 2018 Jul 12. doi: 10.1111/epi.14477. [Epub ahead of print]

PMID:
29998598
8.

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.

Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, Corley S, Prosser-Loose E, Mousseau DD, Lim HJ, Tellez-Zenteno J, Huh L, Leung E, Carmant L, Huntsman RJ.

BMC Pediatr. 2018 Jul 7;18(1):221. doi: 10.1186/s12887-018-1191-y.

9.

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Jul 5;8(1):10154. doi: 10.1038/s41598-018-28127-0. Erratum in: Sci Rep. 2018 Aug 2;8(1):11850.

10.

Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos.

Valim Brigante TA, Abe FR, Zuardi AW, Hallak JEC, Crippa JAS, de Oliveira DP.

Chem Biol Interact. 2018 Aug 1;291:81-86. doi: 10.1016/j.cbi.2018.06.008. Epub 2018 Jun 11.

PMID:
29902416
11.

Addition of Cannabidiol to Current Antiepileptic Therapy Reduces Drop Seizures in Children and Adults With Treatment-Resistant Lennox-Gastaut Syndrome.

Ostrovsky DA, Ehrlich A.

Explore (NY). 2018 Jul - Aug;14(4):311-313. doi: 10.1016/j.explore.2018.04.005. Epub 2018 May 1. No abstract available.

PMID:
29887290
12.

Affiliate stigma and caregiver burden in intractable epilepsy.

Hansen B, Szaflarski M, Bebin EM, Szaflarski JP.

Epilepsy Behav. 2018 Aug;85:1-6. doi: 10.1016/j.yebeh.2018.05.028. Epub 2018 Jun 7.

PMID:
29886019
13.

Cannabidiol and Serum Antiepileptic Drug Levels: The ABCs of CBD With AEDs.

Chang BS.

Epilepsy Curr. 2018 Jan-Feb;18(1):33-34. doi: 10.5698/1535-7597.18.1.33. No abstract available.

14.

Investigational cannabinoids in seizure disorders, what have we learned thus far?

Ružić Zečević D, Folić M, Tantoush Z, Radovanović M, Babić G, Janković SM.

Expert Opin Investig Drugs. 2018 Jun;27(6):535-541. doi: 10.1080/13543784.2018.1482275. Epub 2018 Jun 6. Review.

PMID:
29842819
15.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

16.

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group.

N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.

PMID:
29768152
17.

Chronic exposure to cannabidiol induces reproductive toxicity in male Swiss mice.

Carvalho RK, Santos ML, Souza MR, Rocha TL, Guimarães FS, Anselmo-Franci JA, Mazaro-Costa R.

J Appl Toxicol. 2018 May 16. doi: 10.1002/jat.3631. [Epub ahead of print]

PMID:
29766538
18.

Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.

Hausman-Kedem M, Menascu S, Kramer U.

Brain Dev. 2018 Aug;40(7):544-551. doi: 10.1016/j.braindev.2018.03.013. Epub 2018 Apr 16.

PMID:
29674131
19.

Reefer to the Rescue: The Dope on Cannabidiol as a Multi-Symptom Panacea for Dravet Syndrome.

Gupta A, Santhakumar V.

Epilepsy Curr. 2018 Mar-Apr;18(2):118-120. doi: 10.5698/1535-7597.18.2.118. No abstract available.

20.

Treatment Strategies for Dravet Syndrome.

Knupp KG, Wirrell EC.

CNS Drugs. 2018 Apr;32(4):335-350. doi: 10.1007/s40263-018-0511-y. Review. Erratum in: CNS Drugs. 2018 Jul 20;:.

PMID:
29594870

Supplemental Content

Loading ...
Support Center